Daptomycin in complicated skin and soft tissue infections;Tratamiento con daptomicina en las infecciones complicadas de piel y partes blandas

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 30, Issue SUPPL.1, 2012, Pages 33-37

  Barberán, José ^a   Carmen Farinas M ^b  

^a HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Daptomycin; Skin and soft tissue infections; Staphylococcus aureus

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; DRUG SAFETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; SKIN INFECTION; SOFT TISSUE INFECTION;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84860385559     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(12)70069-1     Document Type: Article

References (64)

1. M.S. Dryden Complicated skin and soft tissue infection J Antimicrob Chemother 65 Suppl 3 2010 iii35 iii44
2. H.F.L. Wertheim, D.C. Melles, M.C. Vos, W. Van Leeuwen, A. Van Belkum, and H.A. Verbrugh The role of nasal carriage in Staphylococcus aureus infections Lancet Infect Dis 5 2005 751 762 (Pubitemid 41688980)
3. E.M. Begier, K. Frenette, N.L. Barrett, P. Mshar, S. Petit, and D.J. Boxrud A highmorbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns Clin Infect Dis 39 2004 1446 1453 (Pubitemid 39518207)
4. P. Koutkia, E. Mylonakis, and J. Boyce Cellulitis: evaluation of possible predisposing factors in hospitalized patients Diagn Microbiol Infect Dis 34 1999 325 327 (Pubitemid 29325047)
5. G.J. Moet, R.N. Jones, D.J. Biedenbach, M.G. Stilwell, and T.R. Fritsche Contemporary causes of skin and soft tissue infections in North America. Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004) Diagn Microbiol Infect Dis 57 2007 7 13 (Pubitemid 44908825)
6. M.S. Dryden Skin and soft tissue infection: microbiology and epidemiology Intern J Antimicrob Agents 34S1 2009 S2 S7
7. M.J. DiNubile, and B.A. Lipsky Complicated infections of skin and skin structures: when the infection is more than skin deep J Antimicrob Chemother 53 Suppl 2 2004 ii37 ii50
8. D.C. Vinh, and J.M. Embil Rapidly progressive soft tissue infections Lancet Infect Dis 5 2005 501 513 (Pubitemid 41022026)
9. J. Mensa, J. Barberan, P. Llinares, J.J. Picazo, E. Bouza, and F. Álvarez Lerma Guía de tratamiento de la infección producida por Staphylococcus aureus resistente a meticilina Rev Esp Quimioter 21 2008 234 258
10. J. Rodríguez-Baño, M.A. Domínguez, A. Blas Millán, C. Borraz, M. Pau González, and B. Almirante Clinical and molecular epidemiology of community-acquired, healthcare-associated and nosocomial methicillin-resistant Staphylococus aureus in Spain Clin Microbiol Infect 15 2009 1111 1118
11. G.E. Schramm, J.A. Johnson, J.A. Doherty, S.T. Micek, and M.H. Kollef Methicillin-resistant Staphylococcus aureus sterilesite infection: The importance of appropriate initial antimicrobial treatment Crit Care Med 34 2006 2069 2074 (Pubitemid 44305607)
12. A.F. Shorr, S.T. Micek, and M.H. Kollef Inappropriate therapy for methicillin- resistant Staphylococcus aureus: resource utilization and cost implications Crit Care Med 36 2008 2335 2340
13. J. Edelsberg, A. Berger, D.J. Weber, R. Mallick, A. Kuznik, and G. Oster Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections Infect Control Hosp Epidemiol 29 2008 160 169 (Pubitemid 351269212)
14. J.K. Johnson, T. Khoie, S. Shurland, K. Kreisel, O.C. Stine, and M.C. Roghmann Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 Clone Emerg Infect Dis 13 2007 1195 1200 (Pubitemid 47359164)
15. E. Cercenado, and E. Ruiz de Gopegui Staphylococcus aureus resistente a la meticilina de origen comunitario Enferm Infecc Microbiol Clin 26 Suppl 13 2008 19 24
16. A. Broseta, F. Chaves, P. Rojo, and J.R. Otero Emergencia de un clon de Staphylococcus aureus resistente a meticilina de origen comunitario en la población pediátrica del sur de Madrid Enferm Infecc Microbiol Clin 24 2006 31 35 (Pubitemid 43288608)
17. A. Manzur, A.M. Domínguez, M. Pujol, M.P. González, E. Limón, and A. Hornero Community-acquired methicillin-resistant Staphylococcus aureus infections: an emerging threat in Spain Clin Microbiol Infect 14 2008 377 380 (Pubitemid 351356530)
18. N. Cobos-Triguero, C. Pitart, F. Marco, J.A. Martínez, M. Almela, and J. López Epidemiología y forma de presentación clínica de las infecciones originadas por Staphylococcus aureus resistente a meticilina productor de leucocidina de Panton-Valentine Rev Esp Quimioter 23 2010 93 99
19. S. Boyle-Vavra, and R.S. Daum Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin Laboratory Investigation 87 2007 3 9 (Pubitemid 44973648)
20. O. Cuevas, E. Cercenado, M.J. Goyanes, A. Vindel, P. Trincado, and T. Boquete Grupo Español para el Estudio de Estafilococo. Staphylococcus spp. en España: situación actual y evolución de la resistencia a antimicrobianos (1986-2006) Enferm Infecc Microbiol Clin 26 2008 269 277 (Pubitemid 351720821)
21. Disponible en: http://www.ecdc.europa.eu/en/activities/surveillance/ EARSNet/Pages/Database.aspx
22. B.P. Howden, P.B. Ward, P.G. Charles, T.M. Korman, A. Fuller, and P. Du Cros Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility Clin Infect Dis 38 2004 521 528 (Pubitemid 38250962)
23. G. Sakoulas, P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellering Jr., and G.M. Eliopoulos Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia J Clin Microbiol 42 2004 2398 2402 (Pubitemid 38747480)
24. M.M. Traczewski, B.D. Katz, J.N. Steenbergen, and S.D. Brown Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007 Antimicrob Agents Chemother 53 2009 1735 1738
25. G. Steinkraus, R. White, and L. Friedrich Vancomycin MIC creep in non-vancomycinintermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 J Antimicrob Agents 60 2007 788 794 (Pubitemid 47434257)
26. A. Soriano, F. Marco, J.A. Martínez, E. Pisos, M. Almela, and V.P. Dimova Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia Clin Infect Dis 46 2008 193 200 (Pubitemid 351269157)
27. J.B. Locke, J. Finn, M. Hilgers, G. Morales, S. Rahawi, and G.C. Kedar Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations Antimicrob Agents Chemother 54 2010 5337 5343
28. G. Morales, J.J. Picazo, E. Baos, F.J. Candel, A. Arribi, and B. Peláez Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolidresistant Staphylococcus aureus Clin Infect Dis 50 2010 821 825
29. M. Sánchez-García, M.A. De la Torre, G. Morales, B. Peláez, M.J. Tolón, and S. Domingo Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit JAMA 303 2010 2260 2264
30. L. Friedman, J.D. Alder, and J.A. Silverman Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus Antimicrob Agents Chemother 50 2006 2137 2145 (Pubitemid 43807536)
31. H.W. Boucher, and G. Sakoulas Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus Clin Infect Dis 45 2007 601 608 (Pubitemid 47328642)
32. S.J. Yang, C.C. Nast, N.N. Mishra, M.R. Yeaman, P.D. Fey, and A.S. Bayer Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms Antimicrob Agents Chemother 54 2010 3079 3085
33. A. Rubio, M. Conrad, R.J. Haselbeck, G.C. Kedar, V. Brown-Driver, and J. Finn Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycinresistant isolates of Staphylococcus aureus Antimicrob Agents Chemother 55 2011 364 367
34. S.J. Van Hal, D.L. Paterson, and I.B. Gosbell Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycinnaïve patient - a review of the literature Eur J Clin Microbiol Infect Dis 30 2011 603 610
35. M.J. Rybak, E. Hershberger, T. Moldovan, and R.G. Grucz In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains Antimicrob Agents Chemother 44 2000 1062 1066 (Pubitemid 30165292)
36. Y.T. Huang, C.H. Liao, L.J. Teng, and P.R. Hsueh Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan Clin Microbiol Infect 14 2008 124 129
37. P.C. Fuchs, A.L. Barry, and S.D. Brown In vitro bactericidal activity of daptomycin against staphylococci J Antimicrob Chemother 49 2002 467 470 (Pubitemid 34223667)
38. E. Loza, M.I. Morosini, A. Pascual, F. Tubau, J. Alcalá, and J. Liñares Actividad comparativa de daptomicina frente a microorganismos grampositivos: programa SENTRY España (2002-2006) Enferm Infecc Microbiol Clin 26 2008 489 494
39. J.J. Picazo, C. Betriu, E. Culebras, I. Rodríguez-Avial, M. Gómez, F. López the VIRA Study Group Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centres Diagn Microbiol Infect Dis 64 2009 448 451
40. J.J. Picazo, C. Betriu, I. Rodríguez-Avial, E. Culebras, F. López, M. Gómez, and V.I.R.A. Grupo Actividad comparativa de la daptomicina frente a Staphylococcus aureus resistente a meticilina y frente a estafilococos coagulasa negativa Enferm Infec Microbiol Clin 28 2010 13 16
41. N. Cotroneo, R. Harris, N. Perlmutter, T. Beveridge, and J.A. Silverman Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus Antimicrob Agents Chemother 52 2008 2223 2225 (Pubitemid 351758562)
42. B.K. English, E.M. Maryniw, A.J. Talati, and E.A. Meals Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin Antimicrob Agents Chemother 50 2006 2225 2227 (Pubitemid 43807550)
43. K.C. Lamp, M.J. Rybak, E.M. Bailey, and G.W. Kaatz In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin Antimicrob Agents Chemother 36 1992 2709 2714
44. C.T.M. Mascio, J.D. Alder, and J.A. Silverman Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells Antimicrob Agents Chemother 51 2007 4255 4260 (Pubitemid 350209874)
45. K. Smith, A. Pérez, G. Ramage, C.G. Gemmell, and S. Lang Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin Int J Antimicrob Agents 33 2009 374 378
46. J. Parra-Ruiz, C. Vidaillac, W.E. Rose, and M.J. Rybak Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm Antimicrob Agents Chemother 54 2010 4329 4334
47. A.L. Baltch, W.J. Ritz, L.H. Bopp, P. Michelsen, and R.P. Smith Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth Antimicrob Agents Chemother 52 2008 1829 1833 (Pubitemid 351614679)
48. D. Begic, C. Von Eiff, and B.T. Tsuji Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype J Antimicrob Chemother 63 2009 977 981
49. R. Wise, T. Gee, J.M. Andrews, B. Dvorchik, and G. Marshall Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers Antimicrob Agents Chemother 46 2002 31 33 (Pubitemid 34031598)
50. F. Traunmüller, M.V. Schintler, J. Metzler, S. Spendel, O. Mauric, and M. Popovic Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections J Antimicrob Chemother 65 2010 1252 1257
51. B.H. Dvorchik, D. Brazier, M.F. DeBruin, and R.D. Arbeit Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects Antimicrob Agents Chemother 47 2003 1318 1323 (Pubitemid 36368592)
52. R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, and B.I. Eisenstein The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections Clin Infect Dis 38 2004 1673 1681 (Pubitemid 38781657)
53. J.E. Krige, K. Lindfield, L. Friedrich, C. Otradovec, W.J. Martone, and D.E. Katz Effectiveness and duration of daptomicyn therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections Curr Med Res Opin 23 2007 2147 2156 (Pubitemid 350246601)
54. B.A. Lipsky, and U. Stoutenburgh Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections J Antimicrob Agents 55 2005 240 245 (Pubitemid 40331152)
55. R.C. Owens Jr., K.C. Lamp, L.V. Friedrich, and R. Russo Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin Am J Med 120 2007 S6 S12
56. B. White, and R.A. Seaton Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin Infect Drug Resist 4 2011 115 127
57. S.L. Davis, P.S. McKinnon, L.M. Hall, G. Delgado Jr., W. Rose, and R.F. Wilson Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes Pharmacotherapy 27 2007 1611 1618 (Pubitemid 350234309)
58. P.E. Pertel, B.I. Eisenstein, A.S. Link, B. Donfrid, E.J.A. Biermann, and P. Bernardo The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erisipelas Int J Clin Pract 63 2009 368 375
59. D.E. Katz, K.C. Lindfield, J.N. Steenbergen, D.P. Benziger, K.J. Blackerby, and A.G. Knapp A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria Int J Clin Pract 62 2008 1304 1305
60. R.S. Chamberlain, D.L. Culshaw, B.J. Donovan, and K.C. Lamp Daptomycin for the treatment of surgical site infections Surgery 146 2009 316 324
61. A.G. Knapp, R.K. Kamepalli, W.J. Martone, and S. Yankelev Prospective, noncomparative study of daptomycin for the treatment of superficial and deep incisional surgical site infections Surg Infect (Larchmt) 12 2011 113 118
62. I.A. Bliziotis, E. Plessa, G. Peppas, and M.E. Falagas Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis Ann Pharmacother 44 2010 97 106
63. J.F. Logman, J. Stephens, B. Heeg, S. Haider, J. Cappelleri, and D. Nathwani Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections Curr Med Res Opin 26 2010 1565 1578
64. R.S. Quist, G. Fierlbeck, R.A. Seaton, J. Loeffler, and R.I. Chaves Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections Intern J Antimicrob Agents 39 2012 90 91